Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Doximity, Inc.NYSE: DOCS
Cost of Revenue · Q2 FY2027 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q2 FY2027 cost of revenue of $25.35M rose 54.3% year over year, ahead of the +43.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.
Context
- Cost of revenue amounted to 10.9% of revenue in FY2026, up 1.1 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +54.3% holds above the trailing-twelve-month pace of +43.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2026
- 70.33M USD
- Year-over-year change
- +25.9%
- 4-year CAGR
- +15.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 70.33M | +25.9% |
| FY2025 | 2025-03-31 | 55.87M | +10.3% |
| FY2024 | 2024-03-31 | 50.67M | -5.3% |
| FY2023 | 2023-03-31 | 53.49M | +34.4% |
| FY2022 | 2022-03-31 | 39.79M | — |
Cost of Revenue vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 cost of revenue of $87.15M is the lowest of the 10 companies compared; the peer median is $1.54B.
- Its year-over-year change of +43.2% is the highest of 10, against a peer median of +8.5%.
- Cost of revenue amounts to 13.2% of revenue for DOCS, versus a peer median of 45.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.6B | +7.3% | -1.7% | 65.2% | |
| LTM Jun 2026 | $6.45B | +11.6% | +3.2% | 78.2% | |
| LTM Jun 2026 | $3.77B | -1.3% | +4.1% | 45.3% | |
| LTM Jun 2026 | $3.48B | +6.6% | +9.1% | 56.1% | |
| LTM Jul 2026 | $1.54B | +15.2% | +11.3% | 36.4% | |
| LTM Jul 2026 | $1.39B | +8.5% | -4.8% | 47.9% | |
| LTM Sep 2026 | $505.6M | +19.5% | +35.5% | 33.5% | |
| LTM Sep 2026 | $445.18M | +36.1% | +30.7% | 34.8% | |
| LTM Jul 2026 | $337.64M | -33.5% | -5.0% | 24.8% | |
| LTM Sep 2026 | $87.15M | +43.2% | +9.6% | 13.2% | |
| Peer median (excluding DOCS) | $1.54B | +8.5% | +4.1% | 45.3% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 343.55M | 419.05M | 475.42M | 570.4M | 644.86M |
| Cost of Revenue | 39.79M | 53.49M | 50.67M | 55.87M | 70.33M |
| Gross Profit | 303.76M | 365.56M | 424.75M | 514.53M | 574.54M |
| Gross Margin | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Research & Development | 62.35M | 80.19M | 81.98M | 93.04M | 130.7M |
| Selling, General & Admin | 127.88M | 160.27M | 170.96M | 191.38M | 228.92M |
| Operating Expenses | 190.23M | 240.45M | 260.88M | 286.73M | 359.62M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| EBITDA | 119.05M | 143.44M | 182.08M | 240.76M | 264.39M |
| EBITDA Margin | 34.7% | 34.2% | 38.3% | 42.2% | 41.0% |
| Operating Income | 113.54M | 125.11M | 163.88M | 227.8M | 214.92M |
| Operating Margin | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Interest Income | 2.15M | 9.29M | 21.66M | 35.85M | 35.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 8.05M | 21.32M | 35.77M | 35.09M |
| Income Before Tax | 114.01M | 133.16M | 185.2M | 263.57M | 250.01M |
| Pre-Tax Margin | 33.2% | 31.8% | 39.0% | 46.2% | 38.8% |
| Income Tax Expense | (40.78M) | 20.34M | 37.62M | 40.39M | 53.95M |
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Net Margin | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| EPS (Basic) | 0.81 | 0.58 | 0.78 | 1.19 | 1.05 |
| EPS (Diluted) | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| Weighted Avg Shares | 163.48M | 193.18M | 190.17M | 186.84M | 187.01M |
| Weighted Avg Shares (Diluted) | 191.02M | 213.43M | 205.73M | 201.21M | 199.05M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.